Why the study?
Myocarditis following COVID-19 mRNA vaccination mostly occurs after the second dose, making presentations after the first dose rare to document.
This case report highlights a rare presentation of myocarditis with a hyperechoic nodule following the first dose of a COVID-19 mRNA vaccine in an adolescent.
Answers are grounded in this paper and cite their sources.
Raises possibility of first-dose myocarditis in adolescents; leaves open incidence and causality.
Myocarditis and/or pericarditis have been reported as adverse events following coronavirus disease 2019 (COVID-19) messenger RNA vaccination, with most cases occurring within 1 week after the second dose. We report a rare case of myocarditis after the first dose of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in a 17-year-old boy. Here, we describe the laboratory, electrocardiographic, and imaging findings of myocarditis.
No takes yet. Share an insight, caveat, or question.
Park et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: